After this past dismal week of trading (less than 100,000 shares traded in the US and closing at 57 cents per share), I have to remind myself why I am still long on this stock

On December 6, 2019, Resverlogix hosted a conference call and published this outline:

"In the near term we will continue our multi-point approach to progressing our corporate commercial value. This approach involves aggressive exploratory development of the following:

• Breakthrough Therapy status filings, both FDA and EMA, over the next 90-120 days

• SGLT2i partnering discussions, one has already been initiated, key patent already filed

• Renal partnering discussions ASAP

• Congestive Heart Failure partnering discussions ASAP, already initiated

• Orphan partnering discussions initially focused on PAH and HIV only at this time. PAH enrollment has already commenced. HIV funding being derived from a yet to be named US based organization

• MoCA partnering discussion in progress"

Subsequently on June 10, 2020 the company was granted Breakthrough Therapy Status by the FDA

In the midst of these grandious results and ambitious plans the world has been struck by a pandemic of Biblical proportions